Best Peptides for DOMS and Post-Workout Soreness

Delayed-onset muscle soreness (DOMS) is the pain and stiffness that develops 12-72 hours after unaccustomed or eccentric-heavy exercise. It results from exercise-induced muscle damage (EIMD) — mechanical disruption of sarcomeres and connective tissue, followed by an inflammatory cascade involving neutrophil infiltration, prostaglandin release, and localized edema. DOMS is not caused by lactic acid (that myth persists but was debunked decades ago). It is a structural and inflammatory event.

DOMS limits training frequency because it reduces force production capacity, restricts range of motion, and signals the nervous system to inhibit maximal contraction in affected muscles. For athletes training 5-6 days per week, managing DOMS is not about comfort — it is about maintaining training quality across sessions.

Several peptides target the underlying mechanisms of EIMD through different pathways. Here is what each one does, what the evidence actually shows, and how to time them.

BPC-157: anti-inflammatory and tissue repair

BPC-157 (Body Protection Compound 157) is a 15-amino-acid gastric peptide fragment that addresses DOMS primarily through its anti-inflammatory and vascular effects.

Mechanism relevant to DOMS. BPC-157 modulates the nitric oxide system, which regulates local blood flow and inflammation. After EIMD, damaged tissue develops localized ischemia and inflammatory mediator accumulation. BPC-157's NO modulation improves perfusion to damaged areas, accelerating the clearance of inflammatory byproducts and delivery of repair substrates. It also downregulates pro-inflammatory cytokines (TNF-alpha, IL-6) and promotes angiogenesis via VEGFR2, supporting new capillary formation in damaged tissue.

Evidence level. Preclinical only. Multiple animal studies show accelerated healing of muscle crush injuries, tendon damage, and ligament tears. No controlled human trials specifically address DOMS. The extrapolation from crush-injury models to exercise-induced microtrauma is plausible but unproven. Practitioner reports are broadly positive for recovery enhancement, but this is anecdotal.

Timing. Most practitioners recommend 250-500 mcg subcutaneously, administered post-workout or before bed. Some protocols use BPC-157 daily throughout training blocks rather than timing it specifically around sessions. Injection near the most-damaged muscle group (e.g., subcutaneous near the quadriceps after heavy squats) is a common approach, though systemic administration also appears effective in animal models.

TB-500: systemic repair signaling

TB-500 is a synthetic fragment of thymosin beta-4, a 43-amino-acid protein involved in cell migration, blood vessel formation, and tissue repair. It targets DOMS through a different mechanism than BPC-157.

Mechanism relevant to DOMS. TB-500 upregulates actin, the protein that forms the cytoskeleton and enables cell movement. After EIMD, repair depends on satellite cell migration to damaged fibers and inflammatory cell trafficking to clear debris. TB-500 promotes both processes by enhancing cellular motility. It also reduces inflammatory cytokine expression and promotes new blood vessel growth in damaged tissue. Critically, TB-500 acts systemically rather than locally — it does not need to be injected near the damage site to exert effects in animal models.

Evidence level. Preclinical. TB-500 has been studied extensively in equine and rodent models for wound healing, cardiac repair, and musculoskeletal recovery. The equine data is notably strong — thymosin beta-4 has been used (and subsequently banned) in racehorse medicine for recovery enhancement. Human clinical data for musculoskeletal applications is limited, though thymosin beta-4 has been studied in human trials for cardiac repair and corneal healing.

Timing. Common protocols use 2-5 mg administered 1-2 times per week (not daily, unlike BPC-157). TB-500 has a relatively long half-life and systemic distribution, so precise workout-relative timing is less critical. Loading phases of twice-weekly dosing for 4-6 weeks followed by weekly maintenance are frequently reported.

MOTS-c: mitochondrial recovery and metabolic resilience

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a mitochondrially derived peptide that represents a different approach to DOMS — targeting the metabolic and mitochondrial damage component rather than the structural or inflammatory component.

Mechanism relevant to DOMS. Intense exercise damages mitochondria in muscle fibers, contributing to impaired energy production and prolonged recovery. MOTS-c activates AMPK (AMP-activated protein kinase), the master energy-sensing enzyme that triggers mitochondrial biogenesis, enhances fatty acid oxidation, and improves glucose uptake in skeletal muscle. By accelerating mitochondrial recovery and biogenesis, MOTS-c addresses the energy production deficit that contributes to post-exercise performance decrements.

Evidence level. Stronger than most peptides in this category. MOTS-c has published human exercise data. A 2024 study in physically active adults showed that MOTS-c administration improved exercise capacity and metabolic markers. Animal studies demonstrate that MOTS-c-treated mice show improved exercise tolerance, enhanced cold tolerance, and resistance to diet-induced obesity. The mechanism — AMPK activation and mitochondrial biogenesis — is well-established in exercise physiology.

Timing. Protocols typically use 5-10 mg administered subcutaneously 2-3 times per week. Some practitioners time doses on training days to support acute metabolic recovery. MOTS-c is not a fast-acting anti-inflammatory — its benefits accumulate over weeks as mitochondrial density and function improve. Expect effects on training capacity and recovery quality rather than acute soreness relief.

Ipamorelin: growth hormone for overnight recovery

Ipamorelin is a GH secretagogue — a peptide that stimulates your pituitary gland to release growth hormone. It addresses DOMS indirectly through the downstream effects of GH and IGF-1 on tissue repair.

Mechanism relevant to DOMS. Growth hormone promotes protein synthesis, collagen production, and cellular repair. The largest natural GH pulse occurs during deep sleep — ipamorelin administered before bed amplifies this pulse, enhancing overnight recovery processes. GH stimulates hepatic IGF-1 production, which directly promotes satellite cell proliferation and muscle fiber repair. The anabolic and anti-catabolic effects of elevated GH/IGF-1 support faster resolution of exercise-induced damage.

Evidence level. GH's role in recovery is well-established in human physiology. Ipamorelin specifically has Phase 2 clinical trial data confirming its ability to stimulate GH release with minimal side effects (it does not significantly raise cortisol or prolactin, unlike older GH secretagogues). However, studies specifically measuring ipamorelin's effect on DOMS or EIMD have not been published. The extrapolation from GH physiology to DOMS recovery is reasonable but indirect.

Timing. 200-300 mcg subcutaneously, administered 30-60 minutes before sleep on an empty stomach (food, especially carbohydrates, blunts GH release). Some practitioners add a second dose in the morning, separated from meals by at least 30 minutes. Evening dosing aligns with the natural nocturnal GH pulse and is generally preferred for recovery applications.

Stacking considerations

BPC-157 and TB-500 are frequently combined because they address complementary repair mechanisms — BPC-157 targets inflammation and local vascular repair while TB-500 promotes systemic cell migration and structural rebuilding. This is the most common peptide recovery stack reported by practitioners.

Adding MOTS-c to a BPC-157/TB-500 stack addresses the mitochondrial dimension that neither healing peptide directly targets. This represents a three-pathway approach: inflammation (BPC-157), structural repair (TB-500), and metabolic recovery (MOTS-c).

Ipamorelin can be layered onto any combination above without mechanistic overlap — it works through the GH/IGF-1 axis, which is upstream and independent of the direct tissue repair pathways targeted by the other three.

Honest evidence assessment

The evidence supporting peptides for DOMS ranges from reasonable physiological extrapolation to genuinely thin. BPC-157 and TB-500 have strong preclinical data for tissue repair but no controlled human DOMS studies. MOTS-c has the best exercise-specific human data of the group. Ipamorelin has solid human data for GH stimulation but its specific impact on DOMS is inferred from GH physiology, not measured directly.

Standard recovery fundamentals — sleep, protein intake, progressive training load management, and adequate hydration — remain the foundation. Peptides are a supplementary layer, not a replacement for the basics. Anyone experiencing DOMS severe enough to consistently impair training should first audit their programming, nutrition, and sleep before adding pharmacological interventions.